From concept to in vivo testing: Microcontainers for oral drug delivery

Chiara Mazzoni, Fábio Tentor, Sophie Strindberg, Line Hagner Nielsen, Stephan Sylvest Keller, Tommy Sonne Alstrøm, Carsten Gundlach, Anette Müllertz, Paolo Marizza, Anja BoisenJournal of Controlled Release 2017 · DOI

TL;DR

This paper presents a novel microcontainer-based oral drug delivery system (DDS) that significantly enhances drug absorption. By fabricating detachable microcontainers (D-MCs) and loading them with ketoprofen using supercritical CO2, the researchers achieved a 180% increase in oral bioavailability within the first 4 hours, marking a crucial step towards clinical translation.

What Problem Does This Paper Address?

Oral drug administration is the preferred route due to its convenience and cost-effectiveness. However, the gastrointestinal (GI) tract presents significant challenges for drug delivery, including harsh acidic conditions in the stomach and enzymatic activity, which can degrade drugs or lead to their premature release. Traditional dosage forms often result in omnidirectional drug release in the intestine, leading to drug loss and reduced absorption. This paper addresses the need for advanced oral DDS that can protect drugs from the GI environment and ensure targeted, efficient release and absorption, thereby improving bioavailability and potentially reducing required dosages.

Methods

The researchers developed a multi-step process for creating and testing their microcontainer-based DDS:

  • Microcontainer Fabrication: Detachable microcontainers (D-MCs) were fabricated on a sacrificial polyacrylic acid (PAA) layer. This layer facilitates handling and detachment of individual D-MCs. The microcontainers themselves were made from epoxy-based photoresist (SU-8) and had a specific cavity size.
  • Drug Loading: Ketoprofen, a BCS class II drug with poor water solubility, was loaded into the D-MCs using supercritical CO2 (scCO2) impregnation. This method was chosen for its efficiency and ability to maintain the drug in an amorphous state, which enhances solubility. Polyvinylpyrrolidone (PVP) was used as a polymer matrix to hold the drug.
  • Enteric Coating: A pH-sensitive polymer, Eudragit® L100, was spray-coated onto the D-MCs to create a gastro-resistant lid. This coating protects the drug from the stomach's acidic environment and is designed to dissolve in the intestine.
  • Characterization: Various techniques were employed to characterize the D-MCs and the drug formulation:
  • X-ray Micro Computed Tomography (X-ray µCT): Used to assess the filling level of the microcontainers and the morphology of the coating.
  • Scanning Electron Microscopy (SEM): Used to visualize the morphology of the loaded and coated D-MCs.
  • Contact Profilometry: Used to measure the thickness of the enteric coating.
  • X-Ray Powder Diffraction (XRPD) and Raman Spectroscopy: Used to determine the solid-state form of ketoprofen, confirming its amorphous state after impregnation.
  • In Vitro Release Studies: The release of ketoprofen from coated and uncoated D-MCs was evaluated in simulated gastric fluid (FaSSGF) and simulated intestinal fluid (FaSSIF) to assess the efficacy of the enteric coating.
  • In Vivo and Ex Vivo Studies:
    • Capsule Preparation: D-MCs were loaded into gelatin capsules for oral administration. A control formulation of amorphous ketoprofen and PVP was also prepared and encapsulated.
  • In Vivo Study: Sprague-Dawley rats were dosed with either D-MC-loaded capsules or control capsules. Plasma concentrations of ketoprofen were measured over time to determine pharmacokinetic parameters like Cmax, Tmax, and AUC, and to calculate relative oral bioavailability.
  • Ex Vivo Study: Rats were sacrificed after dosing, and their GI tracts were examined to locate the D-MCs and understand their distribution, particularly at the time of maximum plasma concentration (Tmax).
  • Statistical Analysis: Standard statistical methods, including Student's t-tests, were used to analyze the data, with p-values below 0.05 considered statistically significant. Effect sizes were calculated using Hedges' g.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Amorphous Ketoprofen Stability: The scCO2 impregnation process, combined with the use of PVP, successfully maintained ketoprofen in its amorphous form, which is crucial for improving its dissolution rate and bioavailability due to its poor water solubility. The amorphous form was stable for at least 7 days.
  • Sacrificial Layer for Handling: The use of a water-soluble PAA layer as a sacrificial substrate significantly improved the handling and detachment of the D-MCs, a critical step for their practical application.
  • Enteric Coating Efficacy: The Eudragit® L100 coating effectively protected ketoprofen from release in the simulated gastric environment, demonstrating its suitability for preventing premature drug release in the stomach.
  • Mucoadhesion and Targeted Release: The ex vivo study suggested that D-MCs, after reaching the intestine, may become embedded in the intestinal mucus. This mucoadhesive property could contribute to a prolonged absorption period and more targeted drug delivery.
  • Translational Potential: The successful demonstration of improved bioavailability in vivo, coupled with a robust fabrication and loading process, highlights the significant potential of these D-MCs for clinical translation.

Key Results

  • Enhanced Bioavailability: D-MCs formulation resulted in a 180% increase in relative oral bioavailability within the first 4 hours compared to the control formulation.
  • Faster Absorption Rate: The time to reach maximum plasma concentration (Tmax) was significantly faster for the D-MCs formulation (93 ± 17 min) compared to the control (212 ± 60 min), indicating a 2.3 times faster absorption.
  • Improved Absorption Rate: The absorption rate (Co to Cmax) was significantly higher for D-MCs (10 ± 2 ng•min⁻¹•mL⁻¹) compared to the control (4 ± 1 ng•min⁻¹•mL⁻¹).
  • In Vitro Release: Coated D-MCs showed only 16 ± 3% ketoprofen release in simulated gastric fluid (FaSSGF) after 120 minutes, compared to 56 ± 14% for uncoated D-MCs. In simulated intestinal fluid (FaSSIF), 100% release was achieved for both coated and uncoated D-MCs within 360 minutes.
  • Microcontainer Dimensions: D-MCs had a height of 304 ± 12 µm, a diameter of 329 ± 5 µm, and an inner reservoir volume of 7.5 ± 0.3 nL.

Limitations and Future Work

  • Gastric Emptying Hypothesis: The faster Tmax observed with D-MCs was hypothesized to be partly due to faster gastric emptying, as the capsules themselves were not coated. Future work could explore fully coated capsules to isolate the effect of the D-MC system itself.
  • Mucoadhesion Mechanism: While mucoadhesion was observed in the ex vivo study, the precise mechanism and its long-term impact on drug release and absorption require further investigation.
  • Long-Term Stability: While amorphous ketoprofen was stable for 7 days, longer-term stability studies under various storage conditions would be beneficial.
  • Scale-Up: While the spray coating method is scalable, further optimization for large-scale manufacturing of the D-MCs and their coating would be necessary for commercialization.
  • Other Drugs: The study focused on ketoprofen. Future research should explore the applicability of this DDS to a wider range of drugs with different physicochemical properties.

Summary updated

BibTeX
@article{mazzoni2017from,
  author = {Chiara Mazzoni and Fábio Tentor and Sophie Strindberg and Line Hagner Nielsen and Stephan Sylvest Keller and Tommy Sonne Alstrøm and Carsten Gundlach and Anette Müllertz and Paolo Marizza and Anja Boisen},
  title = {{From concept to in vivo testing: Microcontainers for oral drug delivery}},
  journal = {Journal of Controlled Release},
  year = {2017},
  doi = {10.1016/j.jconrel.2017.10.013},
}
Figure